F2-isoprostanes as novel biomarkers for type 2 diabetes: A review

Journal of Clinical Biochemistry and Nutrition

Volumn 45, Issue 1, 2009, Pages 1-8

  Kaviarasan, Subramanian ^a   Muniandy, Sekaran ^b   Qvist, Rajes ^a   Ismail, Ikram S ^a  

^a UNIVERSITY MALAYA MEDICAL CENTRE   (Malaysia)

^b UNIVERSITY OF MALAYA   (Malaysia)

Author keywords

Isoprostanes; Lipid peroxidation; Oxidative stress; Type 2 diabetes

Indexed keywords

ISOPROSTANE DERIVATIVE;

ARACHIDONIC ACID METABOLISM; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETIC OBESITY; DYSLIPIDEMIA; GOLD STANDARD; HUMAN; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; LIPID PEROXIDATION; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; REVIEW;

EID: 67849126441     PISSN: 09120009     EISSN: None     Source Type: Journal    
DOI: 10.3164/jcbn.08-266     Document Type: Review

References (56)

1. Halliwell, B. and Gutteridge, J.M.C.: Free radicals in Biology and Medicine, 3rd ed., Clarendon Press, Oxford, 1999.
2. Halliwell, B. and Grootveld, M.: The measurement of free radical reactions in humans. FEBS Lett., 213, 9-14, 1978.
3. Morrow, J.D., Harris, T.M., and Roberts, L.J.: Non- cyclooxygenase oxidative formation of a series of novel prostaglandins: analytical ramifications for measurement of eicosanoids. Anal. Biochem., 184, 1-10, 1990.
4. Mezzetti, A., Cipollone, F., and Cuccurullo, F.: Oxidative stress and cardiovascular complications in diabetes: Isoprostanes and new markers on an old paradigm. Cardiovasc. Res., 47, 475-488, 2000.
5. Pryor, W.A., Stanely, J.P., and Blair, E.: Autoxidation of polyunsaturated fatty acids; II. A suggested mechanism for the formation of TBA-reactive materials from prostaglandin- like endoperoxides. Lipids, 11, 370-379, 1976.
6. Morrow, J.D., Hill, K.E., Burk, R.F., Nammour, T.M., Badr, K.F., and Roberts, L.J.: A series of prostaglandin F2-like compounds are produced in vivo in humans by a non- cyclooxygenase, free radical-catalyzed mechanism. Proc. Natl. Acad. Sci. USA, 87, 9383-9387, 1990.
7. Morrow, J.D. and Roberts, L.J.: The isoprostanes: unique bioactive products of lipid peroxidation. Prog. Lipid Res., 36, 1-21, 1997.
8. Chen, Y., Morrow, J.D., and Roberts, L.J. II.: Formation of reactive cyclopentenone compounds in vivo as products of the isoprostane pathway. J. Biol. Chem., 274, 10863-10868, 1999.
9. Brame, C.J., Salomon, R.G., Morrow, J.D., and Roberts, L.J., II: Identification of extremely reactive γ-ketoaldehydes (isolevuglandins) as products of the isoprostane pathway and characterization of their lysyl protein adducts. J. Biol. Chem., 274, 13139-13146, 1999.
10. 2 receptors. J. Clin. Invest., 90, 136-141, 1992.
11. Wagner, R.S., Weare, C., Jin, N., Mohler, E.R., and Rhoades, R.A.: Characterization of signal transduction events stimulated by 8-epi-prostaglandin (PG) F2 alpha in rat aortic rings. Prostaglandins, 54, 581-599, 1997. (Pubitemid 27444149)
12. Hoffman, S.W., Moore, S., and Ellis, E.F.: Isoprostanes: free radical-generated PGs with constrictor effects on cerebral arteries. Stroke, 28, 844-849, 1997. (Pubitemid 27161473)
13. Hou, X., Roberts, L.J. II., Taber, D.F., Morrow, J.D., Kanai, K., Gobeil, F. Jr., Beauchamp, M.H., Bernier, S.G., Lepage, G., Varma, D.R., and Chemtob, S.: 2,3-Dinor-5,6-dihydro- 15-F(2t)-isoprostane: a bioactive prostanoid metabolite. Am. J. Physiol. Regul. Integr. Comp. Physiol., R391-R400, 2001.
14. Banerjee, M., Kang, K.H., Morrow, J.D., Roberts, L.J., and Newman, J.H.: Effects of a novel prostaglandin, 8-epi-PGF2 alpha, in rabbit lung in situ. Am. J. Physiol., 263, H660-H663, 1992.
15. Bernareggi, M., Rossoni, G., and Berti, F.: Bronchopulmonary effects of 8-epi-PGF2A in anaesthetized guinea pigs. Pharmacol. Res., 37, 75-80, 1998.
16. Lahaie, I., Hardy, P., Hou, X., Hassessain, H., Asselin, P., Lachapelle, P., Almazan, G., Varma, D.R., Morrow, J.D., Roberts, L.J. 2nd., and Chemtob, S.: A novel mechanism for vasoconstrictor action of 8-isoprostaglandin F2 alpha on retinal vessels. Am. J. Physiol., 274, R1406-R1416, 1998.
17. Basu, S.: F2-Isoprostane induced prostaglandin formation in the rabbit. Free Radic. Res., 40, 273-280, 2006.
18. Basu, S.: Radioimmunoassay of 15-keto-13,14-dihydroprostaglandin F2a: an index for inflammation via cyclooxygenase catalysed lipid peroxidation. Prostaglandins Leukot. Essent. Fatty Acids, 58, 347-352, 1998.
19. Scholz, H., Yndestad, A., Damås, J.K., Waehre, T., Tonstad, S., Aukrust, B., and Halvorsen, P.: 8-isoprostane increases expression of interleukin-8 in human macrophages through activation of mitogen-activated protein kinases. Cardiovasc. Res., 59, 945-954, 2003.
20. Patrono, C. and FitzGerald, G.A.: Isoprostanes: potential markers of oxidant stress in atherothrombotic disease. Arterioscler. Thromb. Vasc. Biol., 17, 2309-2315, 1997.
21. 2α. J. Biol. Chem., 272, 27147-27154, 1997.
22. 2-isoprostane stimulates cell proliferation and endothelin-1 expression on endothelial cells. Kidney Int., 56, 471-478, 1999. (Pubitemid 29353144)
23. 2 receptor in vivo. Circulation, 101, 2833-2840, 2000. (Pubitemid 30396015)
24. Morrow, J.D., Minton, T.S., and Roberts, L.J., II: The F2-isoprostane, 8-epi-prostaglandin F2α, a potent agonist of the vascular thromboxane/endoperoxide receptor, is a platelet thromboxane/endoperoxide receptor antagonist. Prostaglandins, 44, 155-163, 1992.
25. Hou, X., Gobeil, F. Jr, Peri, K., Speranza, G., Marrache, A.M., Lachapelle, P., Roberts, L.J. II., Varma., D.R., and Chemtob, S.: Augmented vasoconstriction and thromboxane formation by 15-F2t-isoprostane (8-iso-PGF2α) in immature pig periventricular brain microvessels. Stroke., 31, 516-525, 2000. (Pubitemid 30078191)
26. Sodergren, E., Vessby, B., and Basu, S.: Radioimmunological measurement of F2-isoprostanes after hydrolysis of lipids in tissues. Prostaglandins Leukot. Essent. Fatty Acids, 63, 149-152, 2000.
27. Morrow, J.D., Awad, J.A., Boss, H.J., Blair, I.A., and Roberts, L.J. II.: Non-cyclooxygenase derived prostanoids (F2-isoprostanes) are formed in situ on phospholipids. Proc. Natl. Acad. Sci. USA, 89, 10721-10725, 1992.
28. 2α. FEBS Lett., 428, 32-36, 1998.
29. Basu, S.: Metabolism of 8-iso-PGF2a in the rabbit. Prostaglandins Leukot. Essent. Fatty Acids, 428, 32-36, 1998.
30. Halliwell, B.: Free radicals, antioxidants, and human disease: curiosity, cause, or consequence? Lancet, 10, 721-724, 1994.
31. Roberts, L.J. II. and Morrow, J.D.: Measurement of F2- isoprostanes as an index of oxidative stress in vivo. Free Radic. Biol. Med., 28, 505-513, 2000.
32. Cracowski, J.L., Durand, T., and Bessard, G.: Isoprostanes as a biomarker of lipid peroxidation in humans: physiology, pharmacology and clinical applications. Trends Pharmacol. Sci., 135, 360-366, 2002.
33. Lawson, J.A., Rokach, J., and FitzGerald, G.A.: Isoprostanes: formation analysis and use of indicies of lipid peroxidation in vivo. J. Biol. Chem., 27, 24441-24444, 1999.
34. Basu, S.: Carbon tetrachloride induced lipid peroxidation: eicosanoid formation and its regulation by antioxidants. Toxicology, 189, 113-127, 2003.
35. Baynes, J.W.: Role of oxidative stress in development of complications in diabetes. Diabetes, 40, 405-412, 1991.
36. Miwa, I., Ichimura, N., Sugiura, M., Hamada, Y., and Taniguchi, S.: Inhibition of glucose-induced insulin secretion by 4-hydroxy-2-nonenal and other lipid peroxidation products. Endocrinology, 141, 2767-2772, 2000. (Pubitemid 32250437)
37. Oranje, W.A. and Wolffenbutte, B.H.: Lipid peroxidation and atherosclerosis in type II diabetes. J. Lab. Clin. Med., 134, 19-32, 1992.
38. Davi, G., Ciabattoni, G., Consoli, A., Mezzetti, A., Falco, A., Santarone, S., Pennese, E., Vitacolonna, E., Bucciarelli, T., Costantini, F., Capani, F., and Patrono, C.: In vivo formation of 8-iso-prostaglandin f2alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation, 99, 224-229, 1999.
39. Mezzetti, A., Cipollone, F., and Cuccurullo, F.: Oxidative stress and cardiovascular complications in diabetes: isoprostanes as new markers on an old paradigm. Cardiovasc. Res., 47, 475-488, 2000.
40. Gopaul, N.K., Anggård, E.E., Mallet, A.I., Betteridge, D.J., Wolff, S.P., and Nourooz-Zadeh, J.: Plasma 8-epi-PGF2 alpha levels are elevated in individuals with non-insulin dependent diabetes mellitus. FEBS Lett., 368, 225-229, 1995.
41. Catella-Lawson, F., Kapoor, S., Pratico, D., Braunstein, S.N., Caraballo, V., and FitzGerald, G.A.: Oxidative stress and diabetes mellitus. J. Invest. Med., 44, 223A, 1996. Abstract.
42. 2-isoprostane in vascular smooth muscle cells by elevated glucose and growth factors. Am. J. Physiol., 271, H159-H165, 1996.
43. Davi, G., Gresele, P., Violi, F., Basili, S., Catalano, M., Giammarresi, C., Volpato, R., Nenci, G.G., Ciabattoni, G., and Patrono, C.: Diabetes mellitus, hypercholesterolemia, and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo. Evidence derived from the study of peripheral arterial disease. Circulation, 96, 69-75, 1997.
44. Fam, S.S. and Morrow, J.D.: The isoprostanes: unique products of arachidonic acid oxidation-a review. Curr. Med. Chem., 10, 1723-1740, 2003.
45. Morrow, J.D., Frei, B., Longmire, A.W., Gaziano, J.M., Lynch, S.M., Shyr, Y., Strauss, W.E., Oates, J.A., and Roberts, L.J. 2nd.: Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. N. Engl. J. Med., 332, 1198-1203, 1995.
46. 2-isoprostane evidence of oxidant stress in the insulin resistant, obese Zucker rat: effects of vitamin E. Eur. J. Pharmacol., 377, 89-92, 1999.
47. Boushey, C.J., Beresford, S.A., Omenn, G.S., and Motulsky, A.G.: A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA, 274, 1049-1057, 1995.
48. Voutilainen, S., Morrow, J.D., Roberts, L.J., Alfthan, G., Alho, H., Nyyssonen, K., and Salonen, J.T.: Enhanced in vivo lipid peroxidation at elevated plasma total homocysteine levels. Arterioscler. Thromb. Vasc. Biol., 19, 1263-1266, 1999.
49. 2-isoprostanes, are present in increased amounts in human atherosclerotic lesions. Arterioscler. Thromb. Vasc. Biol., 17, 3236-3241, 1997.
50. Pratico, D., Iuliano, L., Mauriello, A., Spagnoli, L., Lawson, J.A., Rokach, J., Maclouf, J., Violi, F., and FitzGerald, G.A.: Localization of distinct F2-isoprostanes in human atherosclerotic lesions. J. Clin. Invest., 100, 2028-2034, 1997.
51. Haffner, S.M., Lehto, S., Ronnemaa, T., Pyörälä, K., and Laakso, M.: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N. Engl. J. Med., 339, 229-234, 1998.
52. Kannel, W.B. and McGee, D.L.: Diabetes and glucose tolerance as risk factors for cardiovascular disease: The Framingham Study. Diabetes Care, 2, 120-126, 1979.
53. Sowers, J.R.: Diabetes mellitus and cardiovascular disease in women. Arch. Intern. Med., 158, 617-621, 1998.
54. Marlière, S., Cracowski, J.L., Durand, T., Chavanon, O., Bessard, J., Guy, A., Stanke-Labesque, F., Rossi, J.C., and Bessard, G.: The 5-series F(2)-isoprostanes possess no vasomotor effects in the rat thoracic aorta, the human internal mammary artery and the human saphenous vein. Br. J. Pharmacol., 135, 1276-1280, 2002.
55. Montuschi, P., Barnes, P.J., and Roberts, L.J. 2nd.: Isoprostanes: markers and mediators of oxidative stress. FASEB J., 18, 1791 - 1800, 2004.
56. Patrignani, P. and Tacconelli, S.: Isoprostanes and other markers of peroxidation in atherosclerosis. Biomarkers, 10, S24-S29, 2005.